Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia
β Scribed by Lucie Opatrny; Margaret N. Warner
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 87 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Heparin-associated thrombocytopenia with thrombosis (HAW is fatal in 29% and leads to limb amputation in another 21% of patients. Patients with arterial thrombosis do worse than do those with venous thrombosis alone. Heparin-associated thrombocytopenia is mediated through IgG or IgM immunoglobulin f
Heparin-induced thrombocytopenia with thrombosis (HITT) can lead to serious morbidity and may be potentially fatal. We reviewed our experience with this entity over a 4-year period, to determine the following: 1) incidence and type of thrombosis in patients with heparin-induced thrombocytopenia (HIT
Cardiac events include angina, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, and valvular surgery. b Miscellaneous events include trauma, carcinoma of the stomach, carcinoma of the prostate, cirrhosis of liver, renal failure, and scleroderma.
## Abstract We report herein a patient with coronary artery disease that developed heparinβinduced thrombocytopenia after coronary artery bypass graft with resulting thrombosis of multiple saphenous vein grafts and myocardial infarction after heparin exposure. The patient required lepirudin and a c